4D lung imaging process quickly analyzes lung impairments from single X-ray.
4DMedical, an Australian-based medical innovation software company, announced Tuesday it has received 510(k) clearance from the U.S. Food & Drug Administration for its XV Technology™, a four-dimensional lung imaging process.
According to a company statement, XV Technology™ can quickly and automatically analyze functional lung impairments from a single X-ray.
“Our XV Technology™…provides critical information about the functional and structural state of a patient’s lungs in the treatment of illnesses, such as COVID-19, asthma, chronic obstructive pulmonary disease, cystic fibrosis, and lung cancer,” said Andreas Fouras, Ph.D., 4DMedical founder and chief executive officer. “FDA clearance means we can fast track our ‘go-to-market’ strategy to ensure hospitals and doctors in the United States have almost immediate access to our XV Technology™ Ventilation Reports.”
As a software-as-a-service diagnostic tool, the XV process applies 4D proprietary algorithms to identify and quantify any functional impairment. Based on company details, the software creates a ventilation report that can be sent to the hospital for clinicians to use in determining the most effective treatment options and strategies for allocating a facility’s resources.
XV is a secure cloud-subscription service that uses existing hospital and clinical infrastructure to allow imaging departments to electronically send X-rays using existing fluoroscopy equipment to 4D Medical. The entire process, including report generation, lasts three hours, according to company details.
Although the technology is not intended to replace molecular tests as the primary diagnostic method or COVID-19, company officials said, 4DMedical hopes its ventilation reports can play a necessary role in providing quantitative diagnostic support and follow-up for patients who either have or are recovering from the virus.
Can AI Facilitate Improved Dual-Energy X-Ray Screening for Patients at High Risk of Osteoporosis?
June 28th 2024Out of 315 patients identified by artificial intelligence (AI) as being at high risk for osteoporosis, subsequent screening with dual-energy X-ray absorptiometry (DXA) in a randomized controlled trial revealed new-onset osteoporosis in 237 patients.
FDA Clears Mobile C-Arm Device Designed for Complex Vascular Procedures
June 17th 2024Offering a combination of intuitive user-friendly controls and enhanced imaging, the Zenition 90 Motorized C-arm reportedly facilitates workflow efficiencies and bolsters visualization for complex vascular procedures, cardiac interventions, and other clinical procedures.
Qure.ai to Debut Multimodality AI Platform for Lung Cancer Imaging at ASCO 2024
May 29th 2024In addition to detecting missed lung nodules on X-rays, the AI-powered Qure.ai lung cancer continuum platform reportedly automates lung nodule measurement on CT scans and facilitates multimodality reporting.